ClinicalTrials.Veeva

Menu

Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3
Phase 2

Conditions

Ejaculation

Treatments

Drug: UK-390,957

Study type

Interventional

Funder types

Industry

Identifiers

NCT00143117
A3871022

Details and patient eligibility

About

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Premature ejaculation as defined by DSM-IV

Exclusion criteria

  • History of erectile dysfunction

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

51

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems